E4512- A Phase III Double-Blind Trial For Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo For Patients With Tumors Harboring The Anaplastic Lymphoma Kinase (Alk) Fusion Protein
Posted Date: May 15, 2019
- Investigator: Sandra Starnes
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The purpose of this research is to compare any good and bad effects of using the study drug, crizotinib after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.
Criteria:
To Be Eligible: Must Have Alk-Positive Nsclc, Age 18 Or Older, Nonpregnant/Breastfeeding, No Prior Metastatic Cancer Within 5 Years
Keywords:
Lung Cancer, Nsclc, Cancer, Non-Small Cell Lung , E4512
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com